Ceritinib-platinum (IV) -4-phenylbutyrate

Ceritinib-platinum (IV) -4-phenylbutyrate (complex 7) is a Ceritinib (HY-15656) -conjugated Platinum (IV) prodrug with anticancer activity. Ceritinib-platinum (IV) -4-phenylbutyrate induces S-phase arrest, DNA damage responses, and apoptosis. Ceritinib-platinum (IV) -4-phenylbutyrate combines cytotoxicity with immune and anti-invasive activation in cancer cell models. Ceritinib-platinum (IV) -4-phenylbutyrate can be used for cancer research, such as non-small cell lung cancer (NSCLC) [1].

Product Specifications

UNSPSC

12352005

Target

Apoptosis

Related Pathways

Apoptosis

Field of Research

Cancer

Smiles

CC1=CC(NC2=NC=C(C(NC3=CC=CC=C3S(=O)(C(C)C)=O)=N2)Cl)=C(C=C1C4CCN(CC4)C(O[Pt]([NH3])(Cl)([NH3])(OC(CCCC5=CC=CC=C5)=O)Cl)=O)OC(C)C

Molecular Formula

C39H52Cl3N7O7PtS

Molecular Weight

1064.38

References & Citations

[1]Sharkawy S, et al. Crizotinib- or Ceritinib-Conjugated Platinum (IV) Prodrugs As Potent Multiaction Agents Inducing Antiproliferative Effects in 2D and 3D Cancer Cell Models. J Med Chem. 2025 Nov 27;68 (22) :24094-24107.